SCHEMBL23948343

SCHEMBL23948343

CC(C)(C)[S@+]([O-])/N=C/c1cc(F)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 5/20 0.39
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32
TUBA4A P68366 1/20 0.32
TUBB4B P68371 1/20 0.32
TUBB3 Q13509 1/20 0.32
TUBB2A Q13885 1/20 0.32
TUBB8 Q3ZCM7 1/20 0.32
TUBA3E Q6PEY2 1/20 0.32
TUBA1A Q71U36 1/20 0.32
TUBA1C Q9BQE3 1/20 0.32
TUBB6 Q9BUF5 1/20 0.32
TUBB2B Q9BVA1 1/20 0.32
TUBB1 Q9H4B7 1/20 0.32
GRIN2D O15399 2/20 0.32
GRIN3B O60391 2/20 0.32
GRIN1 Q05586 2/20 0.32
GRIN2A Q12879 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19617712 1.00 NFE2L2 (0.39) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL25780171 1.00 NFE2L2 (0.39) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29618134 1.00 NFE2L2 (0.39) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL19617711 1.00 NFE2L2 (0.39) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL19617713 1.00 NFE2L2 (0.39) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL23070616 1.00 NFE2L2 (0.39) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL14809450 0.87 GRIN2D (0.45) NFE2L2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL14809451 0.87 GRIN2D (0.45) NFE2L2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1890678 0.87 GRIN2D (0.45) NFE2L2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL12525147 0.87 GRIN2D (0.45) NFE2L2GRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242536-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS PYRAMID BIOSCIENCES, INC. 2023-08-03 US disclosed
US-20230242536-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS PYRAMID BIOSCIENCES, INC. 2023-08-03 US disclosed
WO-2021211882-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS PYRAMID BIOSCIENCES, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242536-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS LTK, FRK, LCK NFE2L2 4746/4885TUBB4A 2307/4885TUBB 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.